Fast-growing life sciences business Gentronix has been acquired by Danish business Scantox Group, marking a transformative step for the company and its 70 staff.
Gentronix, based in Alderley Park, offers genetic toxicology solutions to global industries, and has seen significant growth over the past five years under the leadership of CEO Matt Tate.
Founded in 1999 by Prof. Richard Walmsley, Gentronix has established itself as a leader in genetic toxicology services. With a global customer base spanning pharmaceutical, biotech, and agrichemical industries, the firm has scaled significantly in recent years. The acquisition by Scantox is seen as a pivotal move, enabling Gentronix to enhance its service offerings and expand its reach further.
The acquisition deal has provided an exit for Mercia Ventures’ Northern Venture Capital Trusts, which sold their stake in Gentronix for £14.8m. This sale represents a 4.5x return on investment, highlighting the financial success and growth trajectory of Gentronix. Under Scantox, Gentronix is set to continue its operations under its current name, while expanding its service portfolio.
Matt Tate, CEO of Gentronix, expressed enthusiasm about the acquisition, highlighting the unique possibilities it brings for both companies. He emphasized the strong strategic rationale behind the merger and the potential for international growth and collaboration.
Alex Gwyther of Mercia Ventures acknowledged the positive impact of patient capital in building a world-class life sciences business. He praised Gentronix’s evolution and momentum over recent years, attributing its success to effective leadership and strategic vision.
Jeanet Løgsted expressed her eagerness to integrate Gentronix’s high-quality standards and client-oriented culture into Scantox, seeing it as a perfect fit for their existing operations and future plans.
The combined expertise of Gentronix and Scantox is anticipated to drive innovation and excellence in genetic toxicology and related fields, setting new standards in the industry.
As the companies integrate their operations and expand their service portfolios, they are expected to set new benchmarks in the field of genetic toxicology and pharmaceutical development. The future looks promising for this new partnership.
This acquisition highlights the importance of strategic partnerships in driving growth and innovation in the life sciences sector. By joining forces, Gentronix and Scantox are poised to create a leading global entity in the field of toxicology and pharmaceutical research.
The acquisition of Gentronix by Scantox marks a significant development in the life sciences industry, promising enhanced services and expanded global reach.
With a strong strategic alignment and shared vision, the partnership is expected to drive growth, innovation, and excellence in genetic toxicology and pharmaceutical development.
